Semax: The Russian Nootropic Peptide Under FDA Review for Stroke and Migraine
Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD.
Regulatory Update (April 2026): Semax is one of seven peptides scheduled for FDA Pharmacy Compounding Advisory Committee review on July 24, 2026. The committee will evaluate Semax for cerebral ischemia, migraine, and trigeminal neuralgia and consider it for the Section 503A Bulk Drug Substances List. Read our full coverage: FDA to Review 7 Peptides for Compounding List in July 2026.
Semax is one of the few therapeutic peptides with decades of real-world clinical use, though almost all of it has taken place outside the United States. Russian researchers developed Semax in the 1980s at the Institute of Molecular Genetics in Moscow. It has been used in Russian hospitals for stroke recovery, cognitive disorders, and a range of neurological conditions. The FDA is now reviewing Semax for the 503A Bulks List in July 2026, with cerebral ischemia, migraine, and trigeminal neuralgia as the uses under evaluation.
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
| Topic | Detail |
|---|---|
| What it is | Synthetic heptapeptide (7 amino acids) derived from ACTH fragment 4-10 |
| Developed in | Russia, 1980s, at the Institute of Molecular Genetics |
| Russian clinical use | Stroke recovery, cognitive disorders, anxiety, optic nerve conditions |
| FDA-reviewed uses | Cerebral ischemia, migraine, trigeminal neuralgia |
| Mechanism | Increases BDNF, modulates neurotransmitter systems, neuroprotective effects |
| Administration | Intranasal spray (most common) |
| FDA status | Not approved; under PCAC review July 24, 2026 for 503A Bulks List inclusion |
What Is Semax?
Semax is a synthetic peptide made of seven amino acids. Its structure is based on a fragment of adrenocorticotropic hormone (ACTH), specifically the 4-10 region of that hormone. Russian researchers modified the natural ACTH fragment by attaching a Pro-Gly-Pro tail, which dramatically improved the peptide’s stability and duration of action without activating the usual ACTH-related stress response. The result was a compound that retained the neurotropic activity of the parent hormone without triggering cortisol release.
How Semax Works
Semax acts on multiple systems in the central nervous system. One of its most important effects is increasing brain-derived neurotrophic factor, or BDNF. BDNF is a protein critical for neuron survival, neuroplasticity, and memory formation. Low BDNF levels are associated with depression, cognitive decline, and neurodegenerative disease. Semax also modulates several neurotransmitter systems including dopamine and serotonin, and it appears to protect neurons from oxidative stress and ischemic damage.
Research on Cerebral Ischemia and Stroke
Cerebral ischemia is the first indication under FDA review. Most of the clinical evidence comes from Russian hospitals, where Semax has been used routinely in acute and subacute stroke care. Studies have shown improved neurological recovery, better functional outcomes, and lower mortality when Semax was added to standard stroke protocols. The mechanism involves direct neuroprotection during the ischemic window plus support for recovery during the subsequent weeks of rehabilitation. English-language reviews of this research are available in journals including Cochrane Database of Systematic Reviews, though quality varies across studies.
Semax for Migraine and Headache
Migraine is the second indication under review. Semax has been studied for various headache conditions in Russian clinical practice. The neuroprotective and neuromodulatory effects that benefit stroke patients may also help the altered brain activity underlying chronic migraine. Published data is more limited than for stroke but the mechanism provides rational support. Some clinicians using Semax off-label for migraine report benefit in patients who have not responded well to conventional preventives.
Semax for Trigeminal Neuralgia
Trigeminal neuralgia is a severely painful condition involving the trigeminal nerve. Standard therapy includes anticonvulsants like carbamazepine and in some cases surgical intervention. The FDA is evaluating Semax as a potential addition to that limited toolkit. The rationale involves the peptide’s neuroprotective properties and its effects on pain signaling pathways. Published evidence for this specific indication is thin but the clinical need is real, and PCAC will examine whether the available data supports compounding for this use.
Semax and Cognition
Outside the official indications under FDA review, Semax has been used in Russia for cognitive enhancement, attention disorders, and optic nerve conditions. It has a reputation in the nootropics community as one of the better-studied cognitive peptides. Users describe improved focus, faster mental processing, and reduced fatigue during demanding cognitive work. These applications are off-label and are not what the FDA will be evaluating in July 2026.
Administration
Semax is most commonly administered as an intranasal spray. Russian clinical formulations are available in various concentrations. The intranasal route allows the peptide to reach the brain efficiently through the nasal mucosa and olfactory pathways. Injection is possible but less common. Dosing is usually measured in drops or small volume sprays per nostril. Protocols vary by indication and should be managed by a licensed clinician.
Safety Profile
Semax has a long track record of clinical use in Russia with a favorable safety profile. Reported side effects are typically mild and include nasal irritation, headache, and occasional overstimulation in sensitive individuals. Because Semax affects neurotransmitter systems, it can interact with antidepressants and other psychoactive medications. Patients taking SSRIs, MAOIs, or stimulants should disclose those medications before starting Semax therapy.
What the FDA Review Will Decide
The PCAC review on July 24, 2026 will examine the available evidence for Semax in cerebral ischemia, migraine, and trigeminal neuralgia. A positive recommendation on even one of these indications would open a legal compounding pathway under Section 503A. Semax is unusual among the peptides under review because it has decades of clinical use and a more extensive published literature, most of which is in Russian. How PCAC handles non-English clinical data will be a significant factor in the outcome.
Cost and Access
Semax is not covered by insurance. Cash-pay costs at compounding pharmacies typically run $150 to $300 per month at common therapeutic doses. Patients considering Semax should work with a licensed physician who can evaluate the underlying neurological condition and monitor progress. Our peptide therapy directory lists verified clinics. For broader context, see our guide to peptide therapy.
